A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131]

Official Title

A Phase III, Open-label, Multicentre, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer

Summary:

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy- naive participants with Stage IV squamous NSCLC.

Trial Description

Primary Outcome:

  • Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)
  • Overall Survival (OS)
Secondary Outcome:
  • Time in Response (TIR) as Determined by the Investigator Using RECIST v1.1
  • PFS as Determined by an Independent Review Facility Using RECIST v1.1
  • Percentage of Participants Alive at 1 and 2 Years
  • Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using European Organisation for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core (QLQ-C30) Subscales
  • Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1
  • Duration of Response as Determined by the Investigator Using RECIST v1.1
  • Time to Response (TTR) as Determined by the Investigator Using RECIST v1.1
  • TTD in Patient-reported Lung Cancer Symptoms Using EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Subscales
  • Change from Baseline in Patient-reported Lung Cancer Symptoms Score using the Symptoms in Lung Cancer (SILC) Scale Symptom Severity Score
  • Percentage of Participants With Adverse Events
  • Percentage of Participants with Anti-therapeutic Antibody (ATA) Response to Atezolizumab
  • Maximum Observed Serum Atezolizumab Concentration (Cmax)
  • Minimum Observed Serum Atezolizumab Concentration (Cmin)
  • Plasma Concentrations for Paclitaxel
  • Plasma Concentrations for Nab-paclitaxel
  • Plasma Concentrations for Carboplatin

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society